How Lalwani was paid
$10.3M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Incentive | Other | Total |
|---|---|---|---|---|---|
| Nikhil LalwaniPresident and Chief Executive Officer | $837,409 | $7,848,711 | $1,572,500 | $20,000 | $10,278,620 |
| Stephen P. CareySenior Vice President, Finance and Chief Financial Officer | $521,031 | $2,130,319 | $582,912 | $17,600 | $3,251,862 |
| Christopher K. MutzSenior Vice President, Head of Rare Disease | $471,625 | $2,130,319 | $477,750 | $317,000 | $3,396,694 |
| Ori GutwergSenior Vice President, Generics | $479,870 | $1,345,411 | $484,278 | — | $2,309,559 |
| Meredith W. CookSenior Vice President, General Counsel and Corporate Secretary | $462,052 | $1,457,614 | $382,032 | $16,724 | $2,318,421 |
What changed and why
- $10.3MCEO total compensation increased to $10,278,620 in 2025 due to higher stock awards and non-equity incentive payouts.
- $883.4MNet revenues reached a record $883.4 million, representing 43.8% year-over-year growth.
- 3%The Compensation Committee approved base salary increases ranging from 3% to 14% for named executive officers.
- 160%Annual incentive bonus payouts ranged from 160% to 200% of target opportunities based on financial and strategic performance.
- 25%Long-term equity incentives utilized a mix of 25% performance-based restricted stock units and 75% time-based restricted stock awards.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.